BIELLO, FEDERICA
 Distribuzione geografica
Continente #
EU - Europa 2.785
AS - Asia 400
NA - Nord America 217
SA - Sud America 40
AF - Africa 9
Totale 3.451
Nazione #
IT - Italia 2.714
US - Stati Uniti d'America 210
SG - Singapore 155
CN - Cina 104
VN - Vietnam 84
FR - Francia 29
BR - Brasile 23
HK - Hong Kong 22
DE - Germania 9
AR - Argentina 8
FI - Finlandia 6
GB - Regno Unito 6
JP - Giappone 5
PH - Filippine 5
TR - Turchia 5
BD - Bangladesh 4
EC - Ecuador 4
ID - Indonesia 4
CA - Canada 3
IN - India 3
NL - Olanda 3
PL - Polonia 3
BE - Belgio 2
CH - Svizzera 2
DZ - Algeria 2
ET - Etiopia 2
IE - Irlanda 2
MX - Messico 2
MY - Malesia 2
PY - Paraguay 2
SE - Svezia 2
UA - Ucraina 2
ZA - Sudafrica 2
AL - Albania 1
AM - Armenia 1
CO - Colombia 1
HN - Honduras 1
IQ - Iraq 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
MU - Mauritius 1
NP - Nepal 1
PE - Perù 1
PK - Pakistan 1
RS - Serbia 1
RU - Federazione Russa 1
SI - Slovenia 1
TN - Tunisia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.451
Città #
Genoa 1.055
Genova 1.000
Rapallo 386
Vado Ligure 247
Singapore 66
San Jose 58
Ashburn 45
Lauterbourg 25
Hanoi 24
Ho Chi Minh City 23
Hong Kong 22
Beijing 18
Council Bluffs 16
New York 13
St Louis 10
Frankfurt am Main 8
Bordighera 6
São Paulo 6
Helsinki 5
Los Angeles 4
Tokyo 4
Biên Hòa 3
Milan 3
Naples 3
Addis Ababa 2
Amsterdam 2
Atlanta 2
Brussels 2
Buffalo 2
Bình Dương 2
City of London 2
Da Nang 2
Davao City 2
Dhaka 2
Dublin 2
Guayaquil 2
Haiphong 2
Hefei 2
Istanbul 2
Johannesburg 2
Kyiv 2
Orem 2
Paris 2
Resistencia 2
Santa Clara 2
Shenzhen 2
Stockholm 2
Thái Nguyên 2
Tianjin 2
Vinh 2
Warsaw 2
Zurich 2
Ancona 1
Arapiraca 1
Artena 1
Asunción 1
Bacoor 1
Baghdad 1
Bari 1
Batna City 1
Belgrade 1
Bengaluru 1
Birmingham 1
Bishkek 1
Braço do Norte 1
Bình Phước 1
Camaçari 1
Cartagena 1
Chicago 1
Chula Vista 1
Cleveland 1
Colonia San Eduardo 1
Cuiabá 1
Dasmariñas 1
Denver 1
Gaziantep 1
General Pico 1
Guangzhou 1
Houston 1
Hải Dương 1
Jakarta 1
Jandira 1
Jiaxing 1
Juiz de Fora 1
Kansas City 1
Kathmandu 1
Kayseri 1
Kingston 1
Kirkwood 1
Kiyosu 1
La Plata 1
Lahore 1
Lappeenranta 1
Lenteng 1
León 1
Lima 1
Ljubljana 1
London 1
Long Xuyen 1
Lublin 1
Totale 3.154
Nome #
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 175
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 172
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 172
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 165
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients 160
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 148
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab 146
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 141
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 141
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 129
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 128
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 128
Afatinib for the treatment of non-small cell lung cancer 126
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 122
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 118
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 118
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 115
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 113
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 112
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 109
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 107
Vinflunine for the treatment of non-small cell lung cancer 101
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 95
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 94
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 89
Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review) 89
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy 82
Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer 74
Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab 56
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study 16
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 11
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 6
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 6
Totale 3.564
Categoria #
all - tutte 14.393
article - articoli 14.393
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.786


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202182 0 0 0 0 0 0 0 0 0 37 26 19
2021/2022296 16 8 10 18 14 23 6 63 36 34 15 53
2022/2023431 27 36 8 39 75 68 0 43 65 5 61 4
2023/2024278 7 24 11 36 20 66 14 25 11 26 4 34
2024/2025684 35 41 17 56 77 69 59 156 24 38 62 50
2025/20261.074 172 20 72 93 170 64 179 50 116 138 0 0
Totale 3.564